What is HC Wainwright’s Forecast for ACTU Q1 Earnings?

Actuate Therapeutics (NASDAQ:ACTU) – Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Actuate Therapeutics in a report issued on Monday, March 17th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($0.26) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.79) EPS and FY2026 earnings at ($0.98) EPS.

Actuate Therapeutics Trading Up 0.8 %

NASDAQ ACTU opened at $7.46 on Wednesday. Actuate Therapeutics has a twelve month low of $5.51 and a twelve month high of $11.73. The firm has a 50-day simple moving average of $8.15 and a 200 day simple moving average of $8.07.

Institutional Trading of Actuate Therapeutics

A number of hedge funds have recently modified their holdings of the company. Sigma Planning Corp acquired a new position in shares of Actuate Therapeutics in the fourth quarter valued at $128,000. Northwestern University bought a new stake in Actuate Therapeutics in the 3rd quarter valued at $207,000. Freestone Capital Holdings LLC bought a new stake in Actuate Therapeutics in the 4th quarter valued at $80,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Actuate Therapeutics in the 4th quarter valued at $84,000. Finally, BIOS Capital Management LP bought a new position in shares of Actuate Therapeutics during the 4th quarter worth about $78,753,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.